HEADER HYDROLASE 02-NOV-06 2J94 TITLE CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX COMPND MOL_ID: 1; COMPND 2 MOLECULE: COAGULATION FACTOR X; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: ACTIVATED DESGLA, RESIDUES 235-488; COMPND 5 SYNONYM: STUART FACTOR, STUART-PROWER FACTOR, ACTIVATED FACTOR XA COMPND 6 HEAVY CHAIN; COMPND 7 EC: 3.4.21.6; COMPND 8 OTHER_DETAILS: DISULPHIDE LINKED TO OTHER CHAIN; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: COAGULATION FACTOR X; COMPND 11 CHAIN: B; COMPND 12 FRAGMENT: ACTIVATED DESGLA, RESIDUES 46-179; COMPND 13 SYNONYM: STUART FACTOR, STUART-PROWER FACTOR, ACTIVATED FACTOR XA COMPND 14 LIGHT CHAIN; COMPND 15 EC: 3.4.21.6; COMPND 16 OTHER_DETAILS: DISULPHIDE LINKED TO OTHER CHAIN SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 OTHER_DETAILS: PURCHASED FROM ENZYME RESEARCH LABS. ISOLATED FROM SOURCE 6 HUMAN BLOOD; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 9 ORGANISM_COMMON: HUMAN; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 OTHER_DETAILS: PURCHASED FROM ENZYME RESEARCH LABS. ISOLATED FROM SOURCE 12 HUMAN BLOOD KEYWDS GAMMA- CARBOXYGLUTAMIC ACID, SERINE PROTEASE, EGF-LIKE DOMAIN, BLOOD KEYWDS 2 COAGULATION, POLYMORPHISM, GLYCOPROTEIN, HYDROXYLATION, GAMMA- KEYWDS 3 CARBOXYGLUTAMIC ACID, CALCIUM, ZYMOGEN, COMPLEX, PROTEASE, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR C.CHAN,A.D.BORTHWICK,D.BROWN,M.CAMPBELL,L.CHAUDRY,C.W.CHUNG, AUTHOR 2 M.A.CONVERY,J.N.HAMBLIN,L.JOHNSTONE,H.A.KELLY,S.KLEANTHOUS, AUTHOR 3 C.L.BURNS-KURTIS,A.PATIKIS,C.PATEL,A.J.PATEMAN,S.SENGER,G.P.SHAH, AUTHOR 4 J.R.TOOMEY,N.S.WATSON,H.E.WESTON,C.WHITWORTH,R.J.YOUNG,P.ZHOU REVDAT 5 13-NOV-24 2J94 1 REMARK REVDAT 4 13-DEC-23 2J94 1 LINK REVDAT 3 24-FEB-09 2J94 1 VERSN REVDAT 2 10-APR-07 2J94 1 JRNL REVDAT 1 20-MAR-07 2J94 0 JRNL AUTH C.CHAN,A.D.BORTHWICK,D.BROWN,C.L.BURNS-KURTIS,M.CAMPBELL, JRNL AUTH 2 L.CHAUDRY,C.W.CHUNG,M.A.CONVERY,J.N.HAMBLIN,L.JOHNSTONE, JRNL AUTH 3 H.A.KELLY,S.KLEANTHOUS,A.PATIKIS,C.PATEL,A.J.PATEMAN, JRNL AUTH 4 S.SENGER,G.P.SHAH,J.R.TOOMEY,N.S.WATSON,H.E.WESTON, JRNL AUTH 5 C.WHITWORTH,R.J.YOUNG,P.ZHOU JRNL TITL FACTOR XA INHIBITORS: S1 BINDING INTERACTIONS OF A SERIES OF JRNL TITL 2 N-{(3S)-1-[(1S) JRNL TITL 3 -1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL} JRNL TITL 4 SULFONAMIDES. JRNL REF J.MED.CHEM. V. 50 1546 2007 JRNL REFN ISSN 0022-2623 JRNL PMID 17338508 JRNL DOI 10.1021/JM060870C REMARK 2 REMARK 2 RESOLUTION. 2.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.3.0006 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 NUMBER OF REFLECTIONS : 17441 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.184 REMARK 3 R VALUE (WORKING SET) : 0.181 REMARK 3 FREE R VALUE : 0.233 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 941 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.10 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.15 REMARK 3 REFLECTION IN BIN (WORKING SET) : 904 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2210 REMARK 3 BIN FREE R VALUE SET COUNT : 46 REMARK 3 BIN FREE R VALUE : 0.3000 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2226 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 32 REMARK 3 SOLVENT ATOMS : 170 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 37.57 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.16000 REMARK 3 B22 (A**2) : -0.87000 REMARK 3 B33 (A**2) : 0.71000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.217 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.186 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.127 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 4.688 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.949 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.916 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2315 ; 0.015 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3127 ; 1.606 ; 1.961 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 284 ; 4.078 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 106 ;31.103 ;24.057 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 392 ;11.206 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 15 ;16.343 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 334 ; 0.111 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 1756 ; 0.006 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 987 ; 0.203 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 1556 ; 0.308 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 164 ; 0.165 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 29 ; 0.145 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 20 ; 0.177 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1459 ; 1.842 ; 2.000 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2263 ; 3.072 ; 4.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 992 ; 4.401 ; 5.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 864 ; 6.200 ; 7.000 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2J94 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 02-NOV-06. REMARK 100 THE DEPOSITION ID IS D_1290030408. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 14-FEB-03 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 6.75 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID29 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9756 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 18402 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.0 REMARK 200 DATA REDUNDANCY : 3.800 REMARK 200 R MERGE (I) : 0.10000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 5.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.21 REMARK 200 COMPLETENESS FOR SHELL (%) : 68.5 REMARK 200 DATA REDUNDANCY IN SHELL : 3.00 REMARK 200 R MERGE FOR SHELL (I) : 0.43000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: PDB ENTRY 1EZQ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 33.72 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.39 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 18% PEG6K, 50MM MES PH 5.85, 5MM REMARK 280 CACL2, 50MM NACL, PH 6.75 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.36950 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 39.46200 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.28150 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 39.46200 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.36950 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.28150 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG A 245 REMARK 465 GLY A 246 REMARK 465 LEU A 247 REMARK 465 PRO A 248 REMARK 465 LYS A 249 REMARK 465 ALA A 250 REMARK 465 LYS A 251 REMARK 465 SER A 252 REMARK 465 HIS A 253 REMARK 465 ALA A 254 REMARK 465 PRO A 255 REMARK 465 GLU A 256 REMARK 465 VAL A 257 REMARK 465 ILE A 258 REMARK 465 THR A 259 REMARK 465 SER A 260 REMARK 465 SER A 261 REMARK 465 PRO A 262 REMARK 465 LEU A 263 REMARK 465 LYS A 264 REMARK 465 GLU B -82 REMARK 465 GLU B -81 REMARK 465 MET B -80 REMARK 465 LYS B -79 REMARK 465 LYS B -78 REMARK 465 GLY B -77 REMARK 465 HIS B -76 REMARK 465 LEU B -75 REMARK 465 GLU B -74 REMARK 465 ARG B -73 REMARK 465 GLU B -72 REMARK 465 CYS B -71 REMARK 465 MET B -70 REMARK 465 GLU B -69 REMARK 465 GLU B -68 REMARK 465 THR B -67 REMARK 465 CYS B -66 REMARK 465 SER B -65 REMARK 465 TYR B -64 REMARK 465 GLU B -63 REMARK 465 GLU B -62 REMARK 465 ALA B -61 REMARK 465 ARG B -60 REMARK 465 GLU B -59 REMARK 465 VAL B -58 REMARK 465 PHE B -57 REMARK 465 GLU B -56 REMARK 465 ASP B -55 REMARK 465 SER B -54 REMARK 465 ASP B -53 REMARK 465 LYS B -52 REMARK 465 THR B -51 REMARK 465 ASN B -50 REMARK 465 GLU B -49 REMARK 465 PHE B -48 REMARK 465 TRP B -47 REMARK 465 ASN B -46 REMARK 465 LYS B -45 REMARK 465 TYR B -44 REMARK 465 LYS B -43 REMARK 465 ASP B -42 REMARK 465 GLY B -41 REMARK 465 ASP B -40 REMARK 465 GLN B -39 REMARK 465 CYS B -38 REMARK 465 GLU B -37 REMARK 465 THR B -36 REMARK 465 SER B -35 REMARK 465 PRO B -34 REMARK 465 CYS B -33 REMARK 465 GLN B -32 REMARK 465 ASN B -31 REMARK 465 GLN B -30 REMARK 465 GLY B -29 REMARK 465 LYS B -28 REMARK 465 CYS B -27 REMARK 465 LYS B -26 REMARK 465 ASP B -25 REMARK 465 GLY B -24 REMARK 465 LEU B -23 REMARK 465 GLY B -22 REMARK 465 GLU B -21 REMARK 465 TYR B -20 REMARK 465 THR B -19 REMARK 465 CYS B -18 REMARK 465 THR B -17 REMARK 465 CYS B -16 REMARK 465 LEU B -15 REMARK 465 GLU B -14 REMARK 465 GLY B -13 REMARK 465 PHE B -12 REMARK 465 GLU B -11 REMARK 465 GLY B -10 REMARK 465 LYS B -9 REMARK 465 ASN B -8 REMARK 465 CYS B -7 REMARK 465 GLU B -6 REMARK 465 LEU B -5 REMARK 465 PHE B -4 REMARK 465 THR B -3 REMARK 465 GLU B 50 REMARK 465 ARG B 51 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 THR A 244 OG1 CG2 REMARK 470 ARG B -2 CG CD NE CZ NH1 NH2 REMARK 470 LYS B -1 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O TYR A 185 O HOH A 2097 2.14 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 48 -178.38 -171.76 REMARK 500 ASP A 164 129.13 -36.27 REMARK 500 ASP A 205 16.16 58.34 REMARK 500 LEU B 0 -126.03 40.45 REMARK 500 GLN B 10 -113.78 -126.59 REMARK 500 LYS B 34 -41.37 -135.92 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 CA A1246 CA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP A 70 OD1 REMARK 620 2 ASN A 72 O 93.2 REMARK 620 3 GLN A 75 O 143.0 81.7 REMARK 620 4 GLU A 80 OE2 95.7 160.4 101.1 REMARK 620 5 HOH A2033 O 90.5 92.6 126.2 70.0 REMARK 620 N 1 2 3 4 REMARK 700 REMARK 700 SHEET REMARK 700 DETERMINATION METHOD: DSSP REMARK 700 THE SHEETS PRESENTED AS "AA" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 8-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 9-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 700 THE SHEETS PRESENTED AS "AB" IN EACH CHAIN ON SHEET RECORDS REMARK 700 BELOW IS ACTUALLY AN 7-STRANDED BARREL THIS IS REPRESENTED BY REMARK 700 A 8-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS REMARK 700 ARE IDENTICAL. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA A1246 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE G15 A1245 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1C5M RELATED DB: PDB REMARK 900 STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, REMARK 900 SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR REMARK 900 RELATED ID: 1EZQ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR128515 REMARK 900 RELATED ID: 1F0R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208815 REMARK 900 RELATED ID: 1F0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH REMARK 900 RPR208707 REMARK 900 RELATED ID: 1FAX RELATED DB: PDB REMARK 900 COAGULATION FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1FJS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031)COMPLEXED REMARK 900 WITH FACTOR XA REMARK 900 RELATED ID: 1FXY RELATED DB: PDB REMARK 900 COAGULATION FACTOR XA-TRYPSIN CHIMERA INHIBITED WITH D-PHE-PRO-ARG- REMARK 900 CHLOROMETHYLKETONE REMARK 900 RELATED ID: 1G2L RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1G2M RELATED DB: PDB REMARK 900 FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 1HCG RELATED DB: PDB REMARK 900 BLOOD COAGULATION FACTOR XA REMARK 900 RELATED ID: 1IOE RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55532 REMARK 900 RELATED ID: 1IQE RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55590 REMARK 900 RELATED ID: 1IQF RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55165 REMARK 900 RELATED ID: 1IQG RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55159 REMARK 900 RELATED ID: 1IQH RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55143 REMARK 900 RELATED ID: 1IQI RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55125 REMARK 900 RELATED ID: 1IQJ RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55124 REMARK 900 RELATED ID: 1IQK RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55113 REMARK 900 RELATED ID: 1IQL RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54476 REMARK 900 RELATED ID: 1IQM RELATED DB: PDB REMARK 900 HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54471 REMARK 900 RELATED ID: 1IQN RELATED DB: PDB REMARK 900 HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55192 REMARK 900 RELATED ID: 1KSN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 FXV673 REMARK 900 RELATED ID: 1KYE RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH (R)-2-(3- ADAMANTAN-1-YL-UREIDO)-3-(3- REMARK 900 CARBAMIMIDOYL- PHENYL)-N-PHENETHYL-PROPIONAMIDE REMARK 900 RELATED ID: 1LPG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79. REMARK 900 RELATED ID: 1LPK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125. REMARK 900 RELATED ID: 1LPZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41. REMARK 900 RELATED ID: 1LQD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45. REMARK 900 RELATED ID: 1MQ5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(4-CHLOROPHENYL) REMARK 900 AMINO]CARBONYL]PHENYL]- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2- REMARK 900 THIOPHENECARBOXAMIDE COMPLEXED WITHHUMAN FACTOR XA REMARK 900 RELATED ID: 1MQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(5-CHLORO-2- REMARK 900 PYRIDINYL)AMINO]CARBONYL ]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2- REMARK 900 OXAZOLYL)METHYLAMINO]METHYL]-2- THIOPHENECARBOXAMIDE COMPLEXED WITH REMARK 900 HUMAN FACTOR XA REMARK 900 RELATED ID: 1MSX RELATED DB: PDB REMARK 900 HUMAN FACTOR XA COMPLEXED WITH 2-[3-(15N- AMINO-15N-IMINO-13C- REMARK 900 METHYL)PHENOXY]-6-[3 -(15N-AMINO-13C-METHYL)PHENOXY]-3,5- DIFLUORO- REMARK 900 4-METHYLPYRIDINE (ZK-806299), BINDING MODELFROM DOUBLE REDOR NMR REMARK 900 AND MD SIMULATIONS. REMARK 900 RELATED ID: 1NFU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR132747 REMARK 900 RELATED ID: 1NFW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR209685 REMARK 900 RELATED ID: 1NFX RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR208944 REMARK 900 RELATED ID: 1NFY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH REMARK 900 RPR200095 REMARK 900 RELATED ID: 1NL8 RELATED DB: PDB REMARK 900 THEORETICAL MODEL OF THE TISSUE FACTOR/ FACTOR VIIA/FACTORXA COMPLEX REMARK 900 RELATED ID: 1P0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEXWITH REMARK 900 ECOTIN M84R REMARK 900 RELATED ID: 1V3X RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -[6-METHYL-4,5,6,7- REMARK 900 TETRAHYDROTHIAZOLO(5, 4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4 -(6- REMARK 900 CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE REMARK 900 RELATED ID: 1WU1 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 4 -[(5-CHLOROINDOL-2-YL) REMARK 900 SULFONYL]-2-(2- METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN -2-YL] REMARK 900 CARBONYL]PIPERAZINE REMARK 900 RELATED ID: 1XKA RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'- REMARK 900 AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 1XKB RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'- REMARK 900 AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID REMARK 900 RELATED ID: 1Z6E RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA COMPLEXED TO RAZAXABAN REMARK 900 RELATED ID: 2BMG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50 REMARK 900 RELATED ID: 2BOH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 1 REMARK 900 RELATED ID: 2BOK RELATED DB: PDB REMARK 900 FACTOR XA - CATION REMARK 900 RELATED ID: 2BQ6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21 REMARK 900 RELATED ID: 2BQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43 REMARK 900 RELATED ID: 2BQW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45 REMARK 900 RELATED ID: 2CJI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2FZZ RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -(3-AMINO-1,2- REMARK 900 BENZISOXAZOL-5-YL)-6-(2 '-(((3R)-3-HYDROXY-1-PYRROLIDINYL)METHYL)-4 REMARK 900 -BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6- TETRAHYDRO-7H-PYRAZOLO[3, REMARK 900 4-C]PYRIDIN-7- ONE REMARK 900 RELATED ID: 2G00 RELATED DB: PDB REMARK 900 FACTOR XA IN COMPLEX WITH THE INHIBITOR 3 -(6-(2'-((DIMETHYLAMINO) REMARK 900 METHYL)-4-BIPHENYLYL )-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7- REMARK 900 TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1- YL)BENZAMIDE REMARK 900 RELATED ID: 2GD4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA- REMARK 900 PENTASACCHARIDE COMPLEX REMARK 900 RELATED ID: 2J2U RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J34 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J38 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J4I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 900 RELATED ID: 2J95 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX REMARK 999 REMARK 999 SEQUENCE REMARK 999 SOME RESIDUES IN CHAIN ARE NOT SEEN IN THE ELECTRON REMARK 999 DENSITY. SEQUENCE DATABASE RESIDUES 1-45 (THE GLA DOMAIN) REMARK 999 WERE BIOCHEMICALLY REMOVED IN CHAIN B DBREF 2J94 A 16 145 UNP P00742 FA10_HUMAN 235 368 DBREF 2J94 A 147 217 UNP P00742 FA10_HUMAN 369 441 DBREF 2J94 A 219 264 UNP P00742 FA10_HUMAN 442 488 DBREF 2J94 B -82 51 UNP P00742 FA10_HUMAN 46 179 SEQRES 1 A 254 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 A 254 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 A 254 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 A 254 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 A 254 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 A 254 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 A 254 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 A 254 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 A 254 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 A 254 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 A 254 GLY ARG THR HIS GLU LYS GLY ARG GLN SER THR ARG LEU SEQRES 12 A 254 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 A 254 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 A 254 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 A 254 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 A 254 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 A 254 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 A 254 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS THR SEQRES 19 A 254 ARG GLY LEU PRO LYS ALA LYS SER HIS ALA PRO GLU VAL SEQRES 20 A 254 ILE THR SER SER PRO LEU LYS SEQRES 1 B 134 GLU GLU MET LYS LYS GLY HIS LEU GLU ARG GLU CYS MET SEQRES 2 B 134 GLU GLU THR CYS SER TYR GLU GLU ALA ARG GLU VAL PHE SEQRES 3 B 134 GLU ASP SER ASP LYS THR ASN GLU PHE TRP ASN LYS TYR SEQRES 4 B 134 LYS ASP GLY ASP GLN CYS GLU THR SER PRO CYS GLN ASN SEQRES 5 B 134 GLN GLY LYS CYS LYS ASP GLY LEU GLY GLU TYR THR CYS SEQRES 6 B 134 THR CYS LEU GLU GLY PHE GLU GLY LYS ASN CYS GLU LEU SEQRES 7 B 134 PHE THR ARG LYS LEU CYS SER LEU ASP ASN GLY ASP CYS SEQRES 8 B 134 ASP GLN PHE CYS HIS GLU GLU GLN ASN SER VAL VAL CYS SEQRES 9 B 134 SER CYS ALA ARG GLY TYR THR LEU ALA ASP ASN GLY LYS SEQRES 10 B 134 ALA CYS ILE PRO THR GLY PRO TYR PRO CYS GLY LYS GLN SEQRES 11 B 134 THR LEU GLU ARG HET G15 A1245 31 HET CA A1246 1 HETNAM G15 5-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2- HETNAM 2 G15 MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1H-1, HETNAM 3 G15 2,4-TRIAZOLE-3-SULFONAMIDE HETNAM CA CALCIUM ION FORMUL 3 G15 C17 H21 CL N6 O5 S2 FORMUL 4 CA CA 2+ FORMUL 5 HOH *170(H2 O) HELIX 1 1 ALA A 55 ALA A 61A 5 8 HELIX 2 2 ARG A 125 LEU A 131A 1 8 HELIX 3 3 ASP A 164 SER A 172 1 9 HELIX 4 4 PHE A 234 THR A 244 1 11 HELIX 5 5 LEU B 3 CYS B 8 5 6 SHEET 1 AA 9 GLN A 20 GLU A 21 0 SHEET 2 AA 9 LYS A 156 VAL A 163 -1 O MET A 157 N GLN A 20 SHEET 3 AA 9 MET A 180 ALA A 183 -1 O CYS A 182 N VAL A 163 SHEET 4 AA 9 GLY A 226 LYS A 230 -1 O GLY A 226 N ALA A 183 SHEET 5 AA 9 THR A 206 TRP A 215 -1 O ILE A 212 N THR A 229 SHEET 6 AA 9 PRO A 198 PHE A 203 -1 O HIS A 199 N THR A 210 SHEET 7 AA 9 THR A 135 GLY A 140 -1 O ILE A 137 N VAL A 200 SHEET 8 AA 9 LYS A 156 VAL A 163 1 O LYS A 156 N GLY A 140 SHEET 9 AA 9 GLN A 20 GLU A 21 -1 O GLN A 20 N MET A 157 SHEET 1 AB 8 GLN A 30 ASN A 35 0 SHEET 2 AB 8 GLY A 40 ILE A 46 -1 N PHE A 41 O LEU A 33 SHEET 3 AB 8 TYR A 51 THR A 54 -1 O LEU A 53 N THR A 45 SHEET 4 AB 8 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 5 AB 8 ALA A 81 LYS A 90 -1 N GLU A 86 O ARG A 107 SHEET 6 AB 8 PHE A 64 VAL A 68 -1 O PHE A 64 N VAL A 85 SHEET 7 AB 8 GLN A 30 ASN A 35 -1 O LEU A 32 N ARG A 67 SHEET 8 AB 8 GLN A 30 ASN A 35 0 SHEET 1 BA 2 PHE B 11 GLU B 15 0 SHEET 2 BA 2 SER B 18 SER B 22 -1 O SER B 18 N GLU B 15 SHEET 1 BB 2 TYR B 27 LEU B 29 0 SHEET 2 BB 2 CYS B 36 PRO B 38 -1 O ILE B 37 N THR B 28 SSBOND 1 CYS A 22 CYS A 27 1555 1555 2.06 SSBOND 2 CYS A 42 CYS A 58 1555 1555 2.07 SSBOND 3 CYS A 122 CYS B 44 1555 1555 2.08 SSBOND 4 CYS A 168 CYS A 182 1555 1555 1.96 SSBOND 5 CYS A 191 CYS A 220 1555 1555 2.03 SSBOND 6 CYS B 1 CYS B 12 1555 1555 2.07 SSBOND 7 CYS B 8 CYS B 21 1555 1555 2.00 SSBOND 8 CYS B 23 CYS B 36 1555 1555 2.07 LINK OD1 ASP A 70 CA CA A1246 1555 1555 2.30 LINK O ASN A 72 CA CA A1246 1555 1555 2.35 LINK O GLN A 75 CA CA A1246 1555 1555 2.33 LINK OE2 GLU A 80 CA CA A1246 1555 1555 2.56 LINK CA CA A1246 O HOH A2033 1555 1555 2.59 SITE 1 AC1 5 ASP A 70 ASN A 72 GLN A 75 GLU A 80 SITE 2 AC1 5 HOH A2033 SITE 1 AC2 17 LYS A 96 GLU A 97 THR A 98 TYR A 99 SITE 2 AC2 17 PHE A 174 ASP A 189 ALA A 190 GLN A 192 SITE 3 AC2 17 VAL A 213 TRP A 215 GLY A 216 GLY A 219 SITE 4 AC2 17 CYS A 220 GLY A 226 ILE A 227 TYR A 228 SITE 5 AC2 17 HOH A2115 CRYST1 56.739 72.563 78.924 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017625 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013781 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012670 0.00000